TGFB1 and metabolic dysfunction-associated steatohepatitis: It has also been reported to downregulate the expression of α-smooth muscle actin (α-SMA) and transforming growth factor-beta (TGF-β), thereby reducing collagen deposition and mitigating the progression of hepatic fibrosis in models of nonalcoholic steatohepatitis [23].